Clinical trial
A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.
NCT00829192 is registered in ClinicalTrials.gov with Clinuvel Pharmaceuticals Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.
- Lead sponsor
- Clinuvel Pharmaceuticals Limited
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- November 30, 2007
- Completion date
- August 31, 2012
- Enrollment
- 200 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
actinic keratoses, carcinoma, squamous cell, organ transplant recipients